Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer

Table 1 Clinicopathological characteristics, n (%)

Variable	All patients	Training set	Validation set
Age (years), mean (± SD)	59.05 (10.45)	58.45 (10.38)	60.48 (10.54)
Sex,
Male	203 (69.8)	144 (70.6)	59 (67.8)
Female	88 (30.2)	60 (29.4)	28 (32.2)
Body mass index (kg/m2), mean (SD)	22.86 (3.22)	22.95 (3.04)	22.65 (3.63)
Radical resection
Yes	274 (94.2)	195 (95.6)	79 (90.8)
No	17 (5.8)	9 (4.4)	8 (9.2)
Primary tumor site
Upper 1/3	11 (3.7)	8 (3.9)	3 (3.4)
Middle 1/3	38 (13.1)	28 (13.7)	10 (11.5)
Low 1/3	208 (71.5)	142 (69.7)	66 (75.9)
Whole	34 (11.7)	26 (12.7)	8 (9.2)
Borrmann type
Ⅰ	32 (11.0)	22 (10.8)	10 (11.5)
Ⅱ	87 (29.9)	63 (30.9)	24 (27.6)
Ⅲ	153 (52.6)	109 (53.4)	44 (50.6)
Ⅳ	19 (6.5)	10 (4.9)	9 (10.3)
Lymph node positivity
Yes	138 (47.4)	99 (48.5)	39 (44.8)
No	153 (52.6)	105 (51.5)	48 (55.2)
Tumor size
< 20 mm	29 (10.0)	18 (8.8)	11 (12.6)
20–50 mm	124 (42.6)	89 (43.6)	35 (40.2)
> 50 mm	138 (47.4)	97 (47.6)	41 (47.1)
Differentiation
Poor	101 (34.7)	72 (35.3)	29 (33.3)
Moderate	149 (51.2)	106 (52.0)	43 (49.4)
Well	26 (8.9)	19 (9.3)	7 (8.0)
Unknown	15 (5.2)	7 (3.4)	8 (9.3)
Lauren type
Intestinal	143 (49.1)	105 (51.5)	38 (43.7)
Diffuse	51 (17.5)	35 (17.2)	16 (18.4)
Mixed	84 (28.9)	58 (28.4)	26 (29.9)
Unknown	13 (4.5)	6 (2.9)	7 (8.0)
TNM stage
Ⅰ	117 (40.2)	81 (39.7)	36 (41.4)
Ⅱ	71 (24.4)	53 (26.0)	18 (20.7)
Ⅲ	89 (30.6)	62 (30.4)	27 (31.0)
Ⅳ	14 (4.8)	8 (3.9)	6 (6.9)
Carcinoembryonic antigen
< 1.97 ng/mL	144 (49.5)	107 (52.5)	37 (42.5)
≥ 1.97 ng/mL	147 (50.9)	97 (47.5)	50 (57.5)
CA199
< 10.19 U/L	145 (49.8)	103 (50.5)	42 (48.3)
≥ 10.19 U/L	146 (50.2)	101 (49.5)	45 (51.7)
CA724
< 2.17 U/L	145 (49.8)	106 (52.0)	39 (44.8)
≥ 2.17 U/L	146 (50.2)	98 (48.0)	48 (55.2)
CA125II
< 10.21 U/L	145 (49.8)	102 (50.0)	43 (49.4)
≥ 10.21 U/L	146 (50.2)	102 (50.0)	44 (50.6)
NLR, mean (SD)	2.63 (2.98)	2.62 (3.03)	2.66 (2.87)
PLR, mean (SD)	148.10 (7.47)	149.64 (78.22)	144.50 (68.87)
SII, mean (SD)	668.08 (768.43)	683.94 (796.04)	630.89 (702.44)
SIRI, mean (SD)	70.69 (29.36)	70.05 (24.26)	72.18 (38.93)
CD3(+) (%), mean (SD)	70.91 (38.40)	69.00 (9.31)	75.41 (68.84)
CD3(+)CD4(+) (%), mean (SD)	40.82 (8.67)	40.79 (8.22)	40.88 (9.69)
CD3(+)CD8(+) (%), mean (SD)	23.42 (8.07)	23.49 (8.02)	23.24 (8.25)
CD4(+)/CD8(+), mean (SD)	2.04 (1.08)	1.99 (0.92)	2.17 (1.37)
CD3(+)CD4(+)CD8(+) (%), mean (SD)	0.54 (1.23)	0.61 (1.44)	0.36 (0.37)
CD19(+) (%), mean (SD)	11.32 (4.71)	11.68 (4.76)	10.48 (4.51)
CD3(-)CD16(+)CD56(+) (%), mean (SD)	16.72 (9.55)	16.25 (8.34)	17.83 (11.02)
CD3(+)CD16(+)CD56(+) (%), mean (SD)	3.13 (4.34)	3.26 (4.89)	2.83 (2.63)

CA125II: Carbohydrate antigen 125II; CA199: Carbohydrate antigen 199; CA724: Carbohydrate antigen 724; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammatory index; SIRI: Systemic inflammation response index.